Low dose heparin for Cardiac Diseases

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Cardiac Diseases+1 More
Heparin - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study whether different doses of anticoagulants given to patients during cardiac catheterization affects the rate of thrombotic complications.

Eligible Conditions
  • Cardiac Diseases

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Other trials for Cardiac Diseases

Study Objectives

2 Primary · 5 Secondary · Reporting Duration: 3 hours

1 day
access site complications
non access site bleeding
time to discharge
1 hour
access site bleeding
hematoma
radial artery occlusion
3 hours
wrist band duration

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Cardiac Diseases

Trial Design

3 Treatment Groups

Low dose heparin
1 of 3
High dose heparin
1 of 3
Placebo
1 of 3
Active Control
Non-Treatment Group

3600 Total Participants · 3 Treatment Groups

Primary Treatment: Low dose heparin · Has Placebo Group · Phase 3

Low dose heparin
Drug
ActiveComparator Group · 1 Intervention: Heparin · Intervention Types: Drug
High dose heparin
Drug
ActiveComparator Group · 1 Intervention: Heparin · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebos · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 hours

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
613 Previous Clinical Trials
396,485 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 12th, 2021

Last Reviewed: October 22nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.